{
    "clinical_study": {
        "@rank": "142730", 
        "arm_group": [
            {
                "arm_group_label": "Low Dose  DE-117", 
                "arm_group_type": "Experimental", 
                "description": "Monotherapy"
            }, 
            {
                "arm_group_label": "Medium Dose DE-117", 
                "arm_group_type": "Experimental", 
                "description": "Monotherapy"
            }, 
            {
                "arm_group_label": "High Dose DE-117", 
                "arm_group_type": "Experimental", 
                "description": "Monotherapy"
            }, 
            {
                "arm_group_label": "Low Dose DE-117 and 0.0015% tafluprost", 
                "arm_group_type": "Experimental", 
                "description": "Adjunctive Therapy"
            }, 
            {
                "arm_group_label": "Med. Dose DE-117 and 0.0015% tafluprost", 
                "arm_group_type": "Experimental", 
                "description": "Adjunctive Therapy"
            }, 
            {
                "arm_group_label": "High Dose DE-117 and 0.0015% tafluprost", 
                "arm_group_type": "Experimental", 
                "description": "Adjunctive Therapy"
            }, 
            {
                "arm_group_label": "0.0015% tafluprost", 
                "arm_group_type": "Active Comparator", 
                "description": "Monotherapy"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Monotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and efficacy of up to three\n      concentrations of DE-117 ophthalmic solution (Low Dose, Medium Dose, and High Dose) as\n      monotherapy and as adjunctive therapy (DE-117 ophthalmic solution with 0.0015% tafluprost)\n      in subjects with primary open-angle glaucoma or ocular hypertension."
        }, 
        "brief_title": "A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT", 
        "completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "condition": "Glaucoma and Ocular Hypertension", 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a two stage study.\n\n      Stage One will explore the dose response of three concentrations of DE-117 as monotherapy\n      compared with 0.0015% tafluprost and placebo. The safety and efficacy of DE-117 as\n      adjunctive therapy (with 0.0015% tafluprost) compared with 0.0015% tafluprost and placebo\n      will also be evaluated. In addition, the additive effect of adjunctive therapy of each\n      concentration will be compared with the corresponding monotherapy concentration.\n\n      Stage Two will assess the safety and efficacy of the optimal DE-117 concentration as\n      monotherapy compared with 0.0015% tafluprost. The safety and efficacy of the optimal DE-117\n      concentration as adjunctive therapy (with 0.0015% tafluprost) compared with DE-117\n      monotherapy and 0.0015% tafluprost will also be evaluated."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or Female, 18 years of age or older\n\n          2. Current diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes\n\n          3. Qualifying intraocular pressure (IOP) in at least one eye at Baseline\n\n        Exclusion Criteria:\n\n          1. Closed/barely open anterior chamber angle or a history of acute angle closure in\n             either eye\n\n          2. Anticipate the need to initiate or modify medication (systemic or topical) that is\n             known to affect intraocular pressure (IOP) during the study period\n\n          3. Females who are pregnant, nursing or planning a pregnancy\n\n          4. Presence of any abnormality or significant illness that could be expected to\n             interfere with the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01654484", 
            "org_study_id": "33-001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Low Dose  DE-117", 
                    "Medium Dose DE-117", 
                    "High Dose DE-117"
                ], 
                "description": "Ophthalmic Solution, QD, 28 Days", 
                "intervention_name": "DE-117", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "0.0015% tafluprost", 
                "description": "Ophthalmic Solution, QD, 28 days", 
                "intervention_name": "0.0015% tafluprost", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Low Dose DE-117 and 0.0015% tafluprost", 
                    "Med. Dose DE-117 and 0.0015% tafluprost", 
                    "High Dose DE-117 and 0.0015% tafluprost"
                ], 
                "description": "Ophthalmic Solutions, QD, 28 days", 
                "intervention_name": "DE-117 and 0.0015% tafluprost", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "Ophthalmic Solution, QD, 28 days", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 14, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Newport Beach", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92663"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Deerfield Beach", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33064"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Largo", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33773"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Morrow", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30260"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roswell", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30076"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "14618"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44115"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Worth", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "76102"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78240"
                    }, 
                    "name": "Santen Investigational Site"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "8", 
        "official_title": "A Phase I/II, Randomized, Observer-masked, Placebo-and Active-controlled, Parallel-group, Multi-center Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change from baseline in intraocular pressure (IOP) on Day 29 at each scheduled time point", 
            "safety_issue": "No", 
            "time_frame": "Day 28 T0 (08:00 \u00b130 mins), T0+2 hrs, T0+4 hrs, T0+8 hrs"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01654484"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Santen Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Santen Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}